Metabolites (Aug 2021)

Increased Fibroblast Growth Factor 21 (FGF21) Concentration in Early Second Trimester Amniotic Fluid and Its Association with Fetal Growth

  • Nikolaos Vrachnis,
  • Savvas Argyridis,
  • Dionysios Vrachnis,
  • Nikolaos Antonakopoulos,
  • Georgios Valsamakis,
  • Christos Iavazzo,
  • Dimitrios Zygouris,
  • Nikolaos Salakos,
  • Alexandros Rodolakis,
  • Nikolaos Vlahos,
  • George Mastorakos,
  • Peter Drakakis,
  • Zoi Iliodromiti

DOI
https://doi.org/10.3390/metabo11090581
Journal volume & issue
Vol. 11, no. 9
p. 581

Abstract

Read online

Altered fetal growth, either reduced or exacerbated, is associated with adverse perinatal outcomes. The underlying pathogenetic mechanisms of altered growth remain unclear. Fibroblast growth factor 21 (FGF21) and insulin are both considered to be major regulators of tissue growth and metabolism. The aim of our study was to investigate the association of second trimester amniotic fluid FGF21 and insulin concentrations with fetal growth. The amniotic fluid concentrations of FGF21 and insulin were determined in 80 cases of different fetal growth patterns (SGA—small for gestational age, LGA—large for gestational age, and AGA—appropriate for gestational age fetuses). Both peptides were found to be increased in cases of abnormal fetal growth, reduced growth velocity (SGA), or macrosomia (LGA). Specifically, FGF21 was significantly increased, as higher FGF21 levels were observed in the amniotic fluid of SGA and LGA fetuses compared with AGA fetuses (p p p > 0.05). Again, the more severe the reduced fetal growth, the higher the insulin levels.

Keywords